Virbac (LTS:0NM7) Piotroski F-Score: 4 (As of Jul. 09, 2026) — 33% Below Median


LTS:0NM7 Virbac SA LTS:0NM7
91 GF Score
Price €322.50
GF Value €364.75
Valuation Modestly Undervalued
! 2 Warning Signs
View Full Analysis

What is Virbac Piotroski F-Score?

Virbac LTS:0NM7 -1.53% 91 Piotroski F-Score is 4 as of Jul. 09, 2026, which is 33% below its 10-year median of 6.00. GuruFocus rates LTS:0NM7 with a GF Score™ of 91/100 and a GF Value™ of €364.75 (Modestly Undervalued). The stock has 2 warning signs investors should review. Among 980 Drug Manufacturers companies, Virbac ranks worse than 61.02% on this metric.

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Virbac has an F-score of 4 indicating the company's financial situation is typical for a stable company.

The historical rank and industry rank for Virbac's Piotroski F-Score or its related term are showing as below:

LTS:0NM7' s Piotroski F-Score Range Over the Past 10 Years
Min: 4   Med: 6   Max: 8
Current: 4

During the past 13 years, the highest Piotroski F-Score of Virbac was 8. The lowest was 4. And the median was 6.

Virbac  (LTS:0NM7) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


Virbac Piotroski F-Score Related Terms


Virbac Piotroski F-Score Historical Data

* Premium members only.

The historical data trend for Virbac's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Virbac Piotroski F-Score Chart

Virbac Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Piotroski F-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only 6.00 6.00 4.00 7.00 4.00

Virbac Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Piotroski F-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.00 0.00 7.00 0.00 4.00

LTS:0NM7 vs LLY, JNJ, ABBV: Piotroski F-Score Comparison

For the Drug Manufacturers - General subindustry, Virbac's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Virbac Piotroski F-Score vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Virbac's Piotroski F-Score distribution charts can be found below:

* The bar in red indicates where Virbac's Piotroski F-Score falls into.


LTS:0NM7
91GF Score
Virbac SA LTS:0NM7
Piotroski F-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Dec25) TTM:Last Year (Dec24) TTM:
Net Income was €151 Mil.
Cash Flow from Operations was €199 Mil.
Revenue was €1,465 Mil.
Gross Profit was €975 Mil.
Average Total Assets from the begining of this year (Dec24)
to the end of this year (Dec25) was (1848.522 + 1914.167) / 2 = €1881.3445 Mil.
Total Assets at the begining of this year (Dec24) was €1,849 Mil.
Long-Term Debt & Capital Lease Obligation was €174 Mil.
Total Current Assets was €792 Mil.
Total Current Liabilities was €516 Mil.
Net Income was €145 Mil.

Revenue was €1,397 Mil.
Gross Profit was €938 Mil.
Average Total Assets from the begining of last year (Dec23)
to the end of last year (Dec24) was (1455.73 + 1848.522) / 2 = €1652.126 Mil.
Total Assets at the begining of last year (Dec23) was €1,456 Mil.
Long-Term Debt & Capital Lease Obligation was €244 Mil.
Total Current Assets was €844 Mil.
Total Current Liabilities was €465 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Virbac's current Net Income (TTM) was 151. ==> Positive ==> Score 1.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Virbac's current Cash Flow from Operations (TTM) was 199. ==> Positive ==> Score 1.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (Dec24)
=150.887/1848.522
=0.08162575

ROA (Last Year)=Net Income/Total Assets (Dec23)
=145.29/1455.73
=0.0998056

Virbac's return on assets of this year was 0.08162575. Virbac's return on assets of last year was 0.0998056. ==> Last year is higher ==> Score 0.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

Virbac's current Net Income (TTM) was 151. Virbac's current Cash Flow from Operations (TTM) was 199. ==> 199 > 151 ==> CFROA > ROA ==> Score 1.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Dec25)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Dec24 to Dec25
=174.177/1881.3445
=0.09258113

Gearing (Last Year: Dec24)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Dec23 to Dec24
=244.277/1652.126
=0.14785616

Virbac's gearing of this year was 0.09258113. Virbac's gearing of last year was 0.14785616. ==> This year is lower or equal to last year. ==> Score 1.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Dec25)=Total Current Assets/Total Current Liabilities
=791.89/516.31
=1.5337491

Current Ratio (Last Year: Dec24)=Total Current Assets/Total Current Liabilities
=844.119/464.56
=1.81702902

Virbac's current ratio of this year was 1.5337491. Virbac's current ratio of last year was 1.81702902. ==> Last year's current ratio is higher ==> Score 0.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

Virbac's number of shares in issue this year was 8.385. Virbac's number of shares in issue last year was 8.379. ==> There is larger number of shares in issue this year. ==> Score 0.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=975.175/1464.677
=0.66579526

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=937.603/1397.379
=0.67097259

Virbac's gross margin of this year was 0.66579526. Virbac's gross margin of last year was 0.67097259. ==> Last year's gross margin is higher ==> Score 0.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (Dec24)
=1464.677/1848.522
=0.79235032

Asset Turnover (Last Year)=Revenue/Total Assets at the Beginning of Last Year (Dec23)
=1397.379/1455.73
=0.95991633

Virbac's asset turnover of this year was 0.79235032. Virbac's asset turnover of last year was 0.95991633. ==> Last year's asset turnover is higher ==> Score 0.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=1+1+0+1+1+0+0+0+0
=4

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Virbac has an F-score of 4 indicating the company's financial situation is typical for a stable company.

Frequently Asked Questions Learn more about Piotroski F-Score →
What does a Piotroski F-Score of 4 mean?
Virbac (LTS:0NM7) has a Piotroski F-Score of 4 as of Jul. 09, 2026. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on Virbac and its competitors. This is 33% below median its historical median of 6.00. Over the past decade, Virbac's Piotroski F-Score has ranged from 4.00 to 8.00. According to the industry distribution chart, Virbac ranks #598 out of 980 companies in the Drug Manufacturers industry, placing it in the top 61%.
Is Virbac's Piotroski F-Score too high?
Virbac's current Piotroski F-Score of 4 is 33% below median its 10-year median of 6.00. Over the past 10 years, this metric has ranged from a low of 4.00 to a high of 8.00. The Drug Manufacturers industry median Piotroski F-Score is 5.00. Virbac's value of 4 is 20% below this industry median. Based on the distribution chart, Virbac ranks #598 out of 980 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Virbac has a GF Score™ of 91/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Virbac's Piotroski F-Score compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Virbac ranks #598 out of 980 companies for Piotroski F-Score. This places Virbac in the lower half of its industry. The industry median Piotroski F-Score is 5.00. Virbac's value of 4 is 20% below this benchmark. Historically, Virbac's own Piotroski F-Score has ranged from 4.00 to 8.00 over the past decade. While the company's 10-year median is 6.00 vs. the industry median of 5.00, Virbac has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Piotroski F-Score for a Drug Manufacturers company?
The median Piotroski F-Score among Drug Manufacturers companies is 5.00, based on 980 companies in the industry. Companies in the top quartile (top 25%) have a Piotroski F-Score significantly above this median, while those in the bottom quartile fall well below. However, Piotroski F-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Virbac's current Piotroski F-Score of 4 is 20% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Piotroski F-Score mean?
A high Piotroski F-Score can signal that a stock is expensive relative to its fundamentals. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on Virbac and its competitors. For the Drug Manufacturers industry, the median Piotroski F-Score is 5.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Virbac's current Piotroski F-Score is 4, which is 33% below median its own 10-year median of 6.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Virbac stock overvalued right now?
Based on GuruFocus' analysis, Virbac (LTS:0NM7) is currently considered Modestly Undervalued. The stock's GF Value™ is €364.75, compared to a current price of €322.50 — trading 11.6% below its estimated fair value. The current Piotroski F-Score is 4, which is 33% below median its 10-year median of 6.00 and 20% below the Drug Manufacturers industry median of 5.00. Virbac's overall GF Score™ is 91/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Piotroski F-Score calculated?
Piotroski F-Score is calculated from a company's financial statements. For Virbac (LTS:0NM7), the current Piotroski F-Score is 4 as of Jul. 09, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Virbac (LTS:0NM7) Overvalued in 2026?

Based on GuruFocus' analysis, Virbac stock appears to be undervalued. The current stock price of €322.50 is trading 11.6% below its estimated GF Value™ of €364.75. GuruFocus considers Virbac to be Modestly Undervalued.

Key valuation signals for LTS:0NM7:

  • Piotroski F-Score: 4 (33% below median its 10-year median of 6.00)
  • GF Value™: €364.75 vs. price of €322.50 (11.6% below fair value)
  • GF Score™: 91/100 with 2 warning signs
  • Industry Position: 20% below the Drug Manufacturers median (#598 of 980)

No single metric tells the full story. See the LTS:0NM7 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Virbac Business Description

Address 13e rue, 1ere avenue 2065, LID - BP 27, Carros, FRA, 06511
Virbac SA is a drug manufacturing company with a focus on animal health. The company generates the vast majority of its revenue in Europe, and it also has its presence in Europe, North America, Far East Asia, India, Africa & Middle East (IMEA), Pacific, and Latin America.
91GF Score

Get the complete analysis for LTS:0NM7

Piotroski F-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€322.50
Price
€364.75
GF Value